Protocol No: CLDK378AIN01 A real-world, open-label, multi-center, prospective, non-interventional (observational) study to evaluate the effectiveness and tolerability of ceritinib in Indian pativvents with ALK positive metastatic non-small cell lung cancer who have progressed or are intolerant to crizotinib.

H9B-MC-BCDM : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy.

H9B-MC-BCDO : A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy.

H9B-MC-BCDP : A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA).

Protocol Addendum H9B-MC-BCDM(1) : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy.

About Somani

Somani Hospital was established on February 1st, 2007 by Dr. Rajkumari Somani. Rajkumari Somani has completed her graduation and post graduation from Shri Ramchandra Medical College, Chennai (Deemed University). It was her dedication and devotion in the field of Obst. and Gynaecology that she established a fully dedicated and developed 20 beded hospital with all modern and state of the art medical and surgical facilities.